Payment overview · 2025
General Payments
$376.74
20 reported records · 10 companies
Healthcare provider profile · identity verified
Sushil Kumar Jain, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MEDINA, OH · NPI 1538147152
Verified facts
What the public records show
CMS Open Payments records show Sushil Kumar Jain, MD received $376.74 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARANESP as an associated drug or biological on 16 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Aranesp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lokelma by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 974 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 974 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $153.03 | 40.6% | 7 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.95 | 16.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $33.14 | 8.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.13 | 8.5% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $18.29 | 4.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.83 | 4.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.33 | 4.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.91 | 4.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.40 | 3.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.73 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $376.74 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $95.08 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $85.04 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $60.95 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $33.14 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.13 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 974 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 198 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ARANESP open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 13 recipient NPIs · example record 1227128438 |
Aranesp · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
198 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
974 | 116 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
974 | 116 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1957 | 303 |
| Amlodipine Besylate | Amlodipine Besylate | 1185 | 212 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1045 | 166 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1018 | 131 |
| Furosemide | Furosemide | 1014 | 163 |
| Eliquis | Apixaban | 974 | 116 |
| Potassium Chloride | Potassium Chloride | 942 | 133 |
| Gabapentin | Gabapentin | 794 | 111 |
| Sertraline Hcl | Sertraline Hcl | 790 | 104 |
| Lisinopril | Lisinopril | 757 | 135 |
| Metoprolol Tartrate | Metoprolol Tartrate | 717 | 126 |
| Tamsulosin Hcl | Tamsulosin Hcl | 592 | 94 |
| Omeprazole | Omeprazole | 564 | 103 |
| Trazodone Hcl | Trazodone Hcl | 493 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 491 | 112 |
| Mirtazapine | Mirtazapine | 488 | 67 |
| Metformin Hcl | Metformin Hcl | 441 | 88 |
| Clopidogrel | Clopidogrel Bisulfate | 438 | 48 |
| Losartan Potassium | Losartan Potassium | 395 | 66 |
| Famotidine | Famotidine | 390 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 352 | 55 |
| Buspirone Hcl | Buspirone Hcl | 342 | 49 |
| Carvedilol | Carvedilol | 332 | 58 |
| Tramadol Hcl | Tramadol Hcl | 308 | 51 |
| Alendronate Sodium | Alendronate Sodium | 283 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 263 | 88 |
| Warfarin Sodium | Warfarin Sodium | 261 | 21 |
| Midodrine Hcl | Midodrine Hcl | 247 | 26 |
| Memantine Hcl | Memantine Hcl | 234 | 33 |
| Cephalexin | Cephalexin | 224 | 110 |
| Meloxicam | Meloxicam | 219 | 35 |
| Simvastatin | Simvastatin | 217 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 215 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 206 | 46 |
| Torsemide | Torsemide | 202 | 41 |
| Donepezil Hcl | Donepezil Hcl | 200 | 34 |
| Farxiga | Dapagliflozin Propanediol | 198 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 196 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 196 | 21 |
| Allopurinol | Allopurinol | 192 | 32 |
| Baclofen | Baclofen | 189 | 23 |
| Risperidone | Risperidone | 182 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 173 | 27 |
| Myrbetriq | Mirabegron | 172 | 17 |
| Levetiracetam | Levetiracetam | 168 | 16 |
| Divalproex Sodium | Divalproex Sodium | 166 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 163 | 16 |
| Prednisone | Prednisone | 162 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 57 |
| Glipizide Er | Glipizide | 147 | 34 |
| Lorazepam | Lorazepam | 144 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 144 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 133 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 131 | 36 |
| Sucralfate | Sucralfate | 130 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 129 | 76 |
| Metformin Hcl Er | Metformin Hcl | 128 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 128 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 127 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 31 |
| Spironolactone | Spironolactone | 119 | 29 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 118 | 19 |
| Montelukast Sodium | Montelukast Sodium | 118 | 19 |
| Xarelto | Rivaroxaban | 115 | 22 |
| Finasteride | Finasteride | 114 | 22 |
| Pregabalin | Pregabalin | 114 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 111 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 109 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 24 |
| Januvia | Sitagliptin Phosphate | 102 | 16 |
| Primidone | Primidone | 99 | suppressed |
| Entresto | Sacubitril/Valsartan | 94 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 53 |
| Alprazolam | Alprazolam | 87 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 81 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 78 | 23 |
| Digoxin | Digoxin | 76 | 15 |
| Venlafaxine Hcl | Venlafaxine Hcl | 76 | 21 |
| Glimepiride | Glimepiride | 75 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 74 | 40 |
| Latanoprost | Latanoprost | 73 | 18 |
| Olanzapine | Olanzapine | 73 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | suppressed |
| Azithromycin | Azithromycin | 71 | 53 |
| Bupropion Xl | Bupropion Hcl | 71 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 70 | suppressed |
| Budesonide | Budesonide | 69 | suppressed |
| Glipizide | Glipizide | 68 | 16 |
| Colesevelam Hcl | Colesevelam Hcl | 66 | suppressed |
| Ezetimibe | Ezetimibe | 63 | suppressed |
| Nystatin | Nystatin | 63 | 36 |
| Topiramate | Topiramate | 63 | suppressed |
| Clonazepam | Clonazepam | 62 | suppressed |
| Ketoconazole | Ketoconazole | 62 | 30 |
| Dicyclomine Hcl | Dicyclomine Hcl | 61 | suppressed |
| Jardiance | Empagliflozin | 61 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 13 |
| Bumetanide | Bumetanide | 59 | suppressed |
| Temazepam | Temazepam | 56 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 49 | 22 |
| Methotrexate | Methotrexate Sodium | 49 | suppressed |
| Fluconazole | Fluconazole | 48 | 22 |
| Insulin Lispro | Insulin Lispro | 48 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 48 | 22 |
| Propranolol Hcl | Propranolol Hcl | 47 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 44 | suppressed |
| Gemtesa | Vibegron | 43 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | suppressed |
| Lactulose | Lactulose | 43 | 12 |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Enulose | Lactulose | 41 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | 12 |
| Methocarbamol | Methocarbamol | 40 | suppressed |
| Lovastatin | Lovastatin | 39 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 38 | 15 |
| Colchicine | Colchicine | 38 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 38 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Xifaxan | Rifaximin | 36 | suppressed |
| Naproxen | Naproxen | 35 | suppressed |
| Novolog Flexpen | Insulin Aspart | 35 | 13 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 34 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Dexamethasone | Dexamethasone | 33 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Permethrin | Permethrin | 33 | 33 |
| Trospium Chloride | Trospium Chloride | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 26 |
| Brimonidine Tartrate | Brimonidine Tartrate | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Vraylar | Cariprazine Hcl | 32 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 31 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 30 | 11 |
| Amoxicillin | Amoxicillin | 29 | 16 |
| Meclizine Hcl | Meclizine Hcl | 29 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 28 | 28 |
| Anastrozole | Anastrozole | 28 | suppressed |
| Calcium Acetate | Calcium Acetate | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 27 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Phenytoin | Phenytoin | 26 | suppressed |
| Cimetidine | Cimetidine | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | 11 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 11 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 24 | suppressed |
| Ursodiol | Ursodiol | 24 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 23 | 14 |
| Metolazone | Metolazone | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Mirabegron Er | Mirabegron | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 12 |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Rytary | Carbidopa/Levodopa | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Alogliptin | Alogliptin Benzoate | 20 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Zonisamide | Zonisamide | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Nadolol | Nadolol | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Aranesp | Darbepoetin Alfa In Polysorbat | 18 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 18 | suppressed |
| Bicalutamide | Bicalutamide | 18 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Galantamine Er | Galantamine Hbr | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 17 | suppressed |
| Nyamyc | Nystatin | 17 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Perphenazine | Perphenazine | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Metformin Er Osmotic | Metformin Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $376.74 · 20 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Arikayce, BREZTRI, CAMZYOS, ELIQUIS, FARXIGA, GEMTESA, GVOKE HYPOPEN, KRYSTEXXA, Korlym, NURTEC ODT, QULIPTA, UBRELVY, Wegovy | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error